Based on meta-analysis data, PD-1 combinations seem superior compared to anti-PD-L1 combinations in NSCLC with conflicting data regarding toxicity, but mostly similar side effects (Brito et al. 2021; Pillai et al. 2018). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.